Podcasts about Civica Rx

For a full transcript of this episode, click here. In this healthcare podcast we're talking about pharmacy acronyms or terms like AWP and WAC, and, not really an acronym, but we'll also talk pharmacy list prices, rebates, discounts. We also have NADAC, but that's slightly off to the side for reasons we'll get to in a sec. Most of these acronyms refer to a number with a dollar sign in front of it, and it's hell on wheels to figure out if and/or to what extent that number reflects what is going on in the real world, especially if you are a patient or a plan sponsor and all you see is the list price that Pharma puts out on one side of the storyboard, and then what the patient pays or (if you're lucky) what the plan pays for the drug on the way other side of the whole chain of events. What's a black box a lot of times for patients and plan sponsors is what goes on in the middle, wherein many middle people get their mitts on the transaction. Real quick here, let's run through the Mister Rogers' neighborhood of all of these middle people right now; and we're gonna do this really briefly. Most of you are already going to know most of this, but I just want to remind you so that when my guest today, Luke Slindee, and I kick into the conversation about the acronyms and the terms and we try to follow the dollar … yeah, you can put a name to a face. Alright, so first we have pharma manufacturers. The pharma manufacturer—and this is largely gonna be true whether it's a branded drug or a generic pharma manufacturer—but the manufacturer sets a list price. This list price is gonna be called an AWP or a WAC price, and we're gonna get into the differences and what those terms actually mean in the show that follows. But Pharma decides their price point. They go to wholesalers with that price. Wholesalers say they want a discount to purchase the product. Some kind of rebate or discount is negotiated. Now the wholesalers have the drug, and they get calls from pharmacies. Pharmacies have patients who have scripts for that, so the pharmacies need to buy the drug. What price does the pharmacy now pay the wholesaler for the drug? Short answer: It's nuts. It's nuts how the wholesalers decide what to charge the pharmacies for the drug. We talk about that in the interview that follows, but suffice to say that now we have the list price turning into whatever price the pharmacies wound up paying to get the drug from the wholesalers for. Any way you cut it, the wholesalers are making some money. Okay … now we get to the part where we're figuring out how much the patient or the plan sponsor will pay to pick up that drug that started at the pharma manufacturers and went to the wholesalers and now is at the pharmacy. How much are the patients gonna pay? How much are the plan sponsors gonna pay? If you spend any time in the real world (not the drug supply chain world), what you'd expect to happen next is that the patient would go into the pharmacy and the pharmacist would charge a markup and/or a dispensing fee on the price that they bought the drug from the wholesaler for. That'd be normal. And this can be the case when patients pay cash. Listen to the show with Mark Cuban (EP418, along with Ferrin Williams, PharmD, MBA), who started a pharmacy called Cost Plus Drugs. Get it? Their prices are cost plus. You have had other pharmacies for years doing similar things, like Blueberry in Pittsburgh. They get the drug. They buy it from a wholesaler or etc. But they buy the drug for some price, and then they sell it to their customers (ie, patients) at their cost plus. But most of the time in pharmacy supply chain world, things don't work that way because many patients have insurance. When a patient walks into the pharmacy, someone has to figure out how much the patient owes and how much their insurance will cover, right? So, enter PBMs (pharmacy benefit managers). They originally started out doing this math (ie, adjudicating claims), figuring out what the out-of-pocket will be for the patient and then what the insurance will cover. Then drugs started to get really expensive and a few other developments, and then, all of a sudden, we have PBMs negotiating with Pharma for how much of a rebate the PBM is going to demand for the PBM to put the manufacturer drug on formulary. The PBM also is determining how much they will pay the pharmacy for said drug on behalf of plan sponsors, in addition to doing the math for how much the patient will pay. So, let me say that again because it kind of begs a “what now?” with eyebrows sky-high as the appropriate response to what I just said, especially if you think through the ramifications here, ramifications which I discuss at length with Vinay Patel (EP241); Benjamin Jolley, PharmD (EP422); Scott Haas (EP365); Paul Holmes (EP397); and others. So, again, the PBM is not just adjudicating claims. They are also negotiating rebates from Pharma so plan sponsors do not have to pay the full amount that the wholesalers paid Pharma and that the pharmacies paid the wholesalers, which maybe is a lot of money. The PBMs are like, “Hey, Pharma. You need to give me a piece of your action because we, the PBM, have big market power. I serve 100 million patients or something. So, if you want access to my 100 million lives, you gotta shell it out. You gotta shell me out some rebates.” So, fine, Pharma gives the PBM some amount of money in the form of a rebate. And it has to work that way, if you think about it, because the drug was originally sold to the wholesaler. You see what I'm saying? So, the pharma company has to give the PBMs a separate rebate amount. This is in addition to how much the PBM told the plan sponsor the plan sponsor owes for the drug, which is also paid to the PBM. But now, PBM is also still in charge of adjudicating the claim. So, they're telling the pharmacy how much to charge the patient. Somehow or another also, the PBM also got itself in charge of deciding how much money the pharmacy itself would be reimbursed by that PBM. In the rest of the world, the pharmacy might tell the PBM, “Hey, this is the price.” But not in pharmacy supply chain world. In pharmacy supply chain world, the PBM tells the pharmacy how much it's gonna pay. The end. And this, my friends, is how so often pharmacies get themselves in the pickle of having to pay the wholesaler one price to get the drug while they get reimbursed a totally different price to dispense the drug. And because independents have very little negotiating leverage on actually either side of that equation, they so very often buy high and sell low. Please listen to the shows with Benjamin Jolley (EP422) and Vinay Patel (EP241), where we get into this in a lot of detail. But I just want to emphasize this point: All of that whole drug supply chain I just went through, where the manufacturer sells to the wholesaler who sells to the pharmacy and the PBM pays the pharmacy and the patient is paying something and the plan sponsor is paying something—many of the middleman transactions in there happen under the cover of darkness a lot of times. If I'm a plan sponsor, do I have any idea how much the PBM paid the pharmacy for any particular drug? Unless you're good at looking at the NADAC numbers (more on this coming up), no. I do not have any idea what a fair price for that drug actually is and how much people are making on the back of that drug as it goes through the supply chain. And this, my friends, is how come spread pricing can exist. Because spread pricing is when the PBM charges the plan sponsor more than they are paying the pharmacy, pocketing the difference, and then calling what they pocket a trade secret—even if it's the plan sponsor whose butt is on the line to make sure that what the PBM is pocketing is fair and reasonable compensation. I mean, if only J&J had listened to this show (EP428). Here's a link to the lawsuit, which is about J&J paying ridiculous amounts in spread pricing. If what I just said is really confusing, I'm gonna validate that and say, “Yeah, it is really confusing.” And to a certain extent, that might be the main point. Where there's mystery, there's margin and all of that. Here's what Dawn Cornelis said on LinkedIn in response to an article about the lawsuit: “Data accessibility lies at the heart of mitigating a fiduciary lawsuit. It all begins with gaining access to your data. But let's be clear—it's not an easy feat. The major hurdle? Procuring accurate data from your TPA [third-party administrator]. And that's just the first step. The subsequent challenge involves analyzing this data, a task best handled by a skilled healthcare data analyst—yet another formidable undertaking.” The one acronym in this whole stew that is not questionable at all is the NADAC. So, let's talk about the NADAC for a moment, the National Average Drug Acquisition Cost Price Benchmark. I was really thrilled to get Luke Slindee to be my guest today—or one reason I was so thrilled—is because Luke works for the accounting firm who, on behalf of CMS (Centers for Medicare & Medicaid Services) and the federal government, administers this NADAC, the National Average Drug Acquisition Cost. (Here's a good NADAC explainer if you're interested.) In brief, NADAC was jointly developed by the Centers for Medicare & Medicaid Services, and it calculates the average price that pharmacies pay for prescription drugs. NADAC is based on a retail price survey. My guest today, as aforementioned, is Luke Slindee. He is a second-generation pharmacist. His family owned a pharmacy in Minnesota when he was growing up. Now he is a senior pharmacy consultant for Myers and Stauffer, which is the accounting firm that calculates the NADAC Price Benchmark on behalf of CMS and the federal government. Also mentioned in this episode are Mark Cuban; Ferrin Williams, PharmD, MBA; Blueberry Pharmacy; Vinay Patel; Benjamin Jolley, PharmD; Scott Haas; Paul Holmes; Dawn Cornelis; Capital Rx; Myers and Stauffer LC; Adam Fein; Joey Dizenhouse; Steven Quimby, MD; and Antonio Ciaccia.   For additional information, go to data.medicaid.gov. You can also follow Luke on LinkedIn.   Luke Slindee, PharmD, is a second-generation pharmacist with a background in independent pharmacy, chain pharmacy, data analytics, and prescription drug pricing. He currently supports public drug pricing transparency benchmarks and is an advocate for pharmacy reimbursement reform and antitrust enforcement in healthcare.   09:52 Why is it important for plan sponsors to understand the going rate for every point in the supply chain? 10:21 How do manufacturers come up with a list price? 10:40 What does AWP stand for? 10:59 What does WAC stand for? 11:06 How are AWP and WAC numbers chosen by the manufacturer? 13:22 What is the difference between AWP and WAC? 14:54 How much are wholesalers paying to manufacturers? 16:43 How much is the pharmacy paying for branded drugs from a wholesaler? 17:34 Why might pharmacies be buying drugs for less than what wholesalers are paying? 18:17 Substack article by Benjamin Jolley, PharmD, on this topic. 19:22 EP423 with Joey Dizenhouse. 20:33 Why do things get weird when a PBM gets involved? 21:58 How does all of this work for generic manufacturers? 25:20 EP344 with Steven Quimby, MD. 26:15 How did Civica Rx come about? 32:21 What's the difference between the NADAC and the AWP value? 36:04 Luke discusses the downstream effects to pharmacies.   For additional information, go to data.medicaid.gov. You can also follow Luke on LinkedIn.   Luke Slindee discusses #followingthedollar through #WAC, #AWP & #NADAC on our #healthcarepodcast. #healthcare #podcast #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Julie Selesnick, Rik Renard, AJ Loiacono (Encore! EP379), Nina Lathia, Marshall Allen, Stacey Richter (INBW39), Peter Hayes, Joey Dizenhouse, Benjamin Jolley, Emily Kagan Trenchard (Encore! EP392)

Imagine a unique governance structure that safeguards its mission against the volatile tides of the market. In this episode, Dan Liljenquist, the board chair of Civica Rx, joins Kedar and Don to shed light on Civica's remarkable mission of making essential generic medications both accessible and affordable to patients across the nation. Dan shares how Civica Rx has already had a profound impact, with over 125 million units of essential medicines supplied to over 1500 U.S. hospitals, and is changing the game in terms of pricing, shortages, and market stability. He explains the ethics behind Civica Rx, the non-profit model ensuring the organization's governance and its steadfast commitment to transparency in pricing, aiming at a fair, sustainable market price for all. Dan also discusses the potential expansion of this model into other areas of healthcare, the challenges posed by monopolies in the drug supply, and how Civica Rx is using its leverage to address systemic issues and stabilize a market fraught with abuse and failure. Tune in to this episode for a deep dive into Civica's revolutionary model aiming to ensure drug availability and pricing stability. Learn more about your ad choices. Visit megaphone.fm/adchoices

Recorded live at the 11th Annual Becker's Healthcare CEO + CFO Roundtable, this episode features Dan Liljenquist, Chief Strategy Officer at Intermountain Healthcare and Board Chair at Civica Rx.  Here, he discusses the issues with increased denials, the shifting regulatory landscape, and more.This episode is brought to you by R1 RCM, a leading provider of technology-driven solutions that transform the financial performance of hospitals, health systems, and medical groups. R1 delivers proven, scalable operating models that power sustainable improvements to net patient revenue, while reducing operating costs. To learn how you can build a future-ready revenue cycle today, visit us at www.r1rcm.com/beckers 

On this episode, I was joined by Martin Van Trieste, Author of Protecting the Patient at All Costs: The Drug Watch Dogs and is the Former Chief Quality Officer at Amgen and Former CEO at Civica Rx. Martin and I discuss: - Protecting the Patient at All Costs - Quality Leadership and being a Chief Quality Officer in Big Pharma - Supply Chain Security - Generic Drugs and Shortages Martin Van Trieste is an accomplished entrepreneur, board governance expert, executive coach and biopharmaceutical executive. Martin Van Trieste is the Former President and CEO of Civica Rx. Prior to joining Civica Rx, he worked with Amgen, a leading biotechnology company and also previously served as vice president of worldwide quality for Bayer Healthcare's Biological Products Division and vice president of quality assurance for the Hospital Products Division for Abbott Laboratories. Van Trieste has also taken on ventures of his own. He's the founder of Rx-360, an international nonprofit organization that enhances patient safety by increasing security and quality in the biopharmaceutical supply chain. He has also served as the chairman of the Parenteral Drug Association (PDA) Board of Directors and was honored with the 2020 Joseph B. Sprowls Lecturer award. 

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Insulin-maker Sanofi lowers its prices and also acquires Provention, clinical trials begin on an out-patient surgery that could help treat type 2 diabetes, a swimmer DQ'd for the tape on his CGM gets the systemic changes he'd pushed for and more! Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode Transcription: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Athletic Greens ● AG1 is way more than greens. XX XX Provention Bio's been in a news a lot lately after the approval of Tzield to delay the development of type 1. Now French insulin-maker Sanofi has agreed to acquire it. The deal builds on an existing co-promotion agreement and gives Sanofi full ownership of the drug. Sanofi makes long acting Toujeo and Lantus. Interestingly, Sanofi has said they're gong to stop further work on type 2 diabetes and obesity drugs. They also joined Novo Nordisk and Eli Lilly in dropping the price of insulin in the US. https://www.reuters.com/markets/deals/frances-sanofi-acquire-us-based-provention-bio-29-bln-2023-03-13/ XX Insulin pricing staying in the news as Senators Bernie Sanders and Cori Bush introduced legislation to cap the price at 20-dollars. They point out the recent prices cuts don't apply to everyone and are still at the whim of the manufacturers. XX California signs up with Civica Rx to produce its own insulin and sell it at an affordable price. The $50 million investment will allow California to produce insulin to be sold at prices capped at $30 per vial and $55 for a box of five prefilled pens, Civica Rx said (PDF) in a release. The agreement is part of the state's CalRx Biosimilar Insulin Initiative. Utah-based Civica Rx is a nonprofit, social welfare manufacturer of generic drugs. This is a long way off.. Civica Rx still needs to gain approval for its biosimilar versions of Sanofi's Lantus (gargline), Eli Lilly's Humalog (lispro) and Novo Nordisk's Novolog (aspart). The cost of insulin would be same for all patients regardless of their insurance situation https://www.fiercepharma.com/manufacturing/california-invests-50m-partner-civica-rx-insulin-manufacturing XX XX (skip?) Millions of Americans with diabetes have cheered as drugmakers slashed the price of insulin, the lifesaving medication that treats the chronic disease. But those lower prices, which came amid government pressure to cap insulin costs and more competition from generics and biosimilars, are only one part of the cost of treating the disease, which causes elevated blood sugar that can damage the heart, eyes and kidneys if untreated. Over-the-counter medical supplies to monitor glucose levels and administer medications can make up the largest portion of a patient's costs. A 2020 JAMA Internal Medicine report found that children and adults with private health insurance spent more out-of-pocket on diabetes-related supplies than on insulin A person with diabetes who uses insulin typically spends $4,882 a year on treatment if they have insurance. Of that, $3,992 is spent on supplies, according to an analysis by GoodRx, or more than 80% of the annual expense of managing the disease https://www.usatoday.com/story/money/personalfinance/2023/03/19/cost-diabetes-supplies-worse-than-insulin/11472381002/ XX New trial of a technique to slow the progression of type 2 diabetes. It's a simple outpatient surgery conducted in the early stages of diagnosis. The procedure targets the doo-oh-DEE-num duodenum, the first section of the small intestine just past the stomach. This organ plays a key role in digestion, including regulating insulin and blood glucose levels. In patients with type 2 diabetes, the cells that line the duodenum have become damaged, and the trial's hypothesis is that removing these cells helps healthy ones to grow back, improving the regulation of blood glucose levels. Patients in the clinical trial would undergo an endoscopy to insert a device into the doo-oh-DEE-num duodenum, which removes those dysfunctional cells with a series of electrical pulses. The procedure itself is only minimally invasive – it takes about an hour, it's conducted under a general anaesthetic and the patient is discharged the same day. Early results seem encouraging. Patients who have undergone the procedure in recent months have already seen their blood glucose levels drop. BTW if you live near L-A they're still recruiting for this. You have to have a type 2 diagnosis and not yet need insulin injections. https://newatlas.com/medical/diabetes-prevent-slow-progression-procedure-clinical-trial/ XX Another study showing automated insulin delivery systems work well and are safe, this one the Tandem Control IQ in little kids. That's only approved right now for kids as young as six.. this study looked at children ages two to six. The hybrid closed-loop system added an average of about 3 hours in ideal blood glucose range over the 13 weeks, compared to no change with standard care. Standard care here meant either an insulin pump or multiple daily injections plus a separate Dexcom G6 CGM. https://www.medscape.com/viewarticle/989673 XX Follow up! Two years ago we told you about Ethan Orr, a Colorado high school swimmer disqualified at a state meet because of the tape over his CGM. Orr's family filed a complaint with the department of justice and the US Attorney in Colorado took up the case. They weren't seeking any financial damages, just a change in policy, which they got. The changes include allowing medical tape with documentation, a way to evaluate requests from students with disabilities who might need reasonable modifications of rules, and a way for refs or coaches to seek on the spot reasonable modifications. - “I knew I'd have to fight my disease to swim, but I never imagined I'd have to fight discrimination to swim,” Ethan said, according to the news release from the law firm. XX Athletic Greens XX Today, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, presented the inaugural Mary Tyler Moore Awards to three women leaders in Congress who have been instrumental in the fight against T1D. U.S. Senators Susan Collins (R-ME) and Jeanne Shaheen (D-NH), co-chairs of the Senate Diabetes Caucus, were honored alongside Representative Diane DeGette (D-CO), co-chair of the Congressional Diabetes Caucus, for their longstanding support of the T1D community. The ceremony, held during JDRF's annual Government Day, honored the legacy of screen icon Mary Tyler Moore, who was diagnosed with T1D at the age of 33. As international chairman of JDRF from 1984 to 2017, Moore used her influence to bring government, scientists and people living with diabetes together to further T1D advocacy and innovation. JDRF (PRNewsFoto/JDRF) JDRF (PRNewsFoto/JDRF) One of Moore's most significant achievements as JDRF international chairman was increased Congressional funding for the Special Diabetes Program at the National Institutes of Health that has accelerated the pace of type 1 diabetes research. This long-term investment in diabetes research has led to significant scientific breakthroughs including Tzield, the first disease modifying treatment for T1D which can delay the onset of the disease by over two years. JDRF Government Day volunteers, more than 175 T1D advocates from across the country, will encourage members of Congress to renew the Special Diabetes Program when they visit lawmakers later today on Capitol Hill. https://finance.yahoo.com/news/jdrf-presents-inaugural-mary-tyler-110000226.html XX On the podcast next week.. . That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

This year kicks off the second decade of Fierce Medtech's annual Fierce 15 report. Not surprisingly, the startups featured on this year's list are raising the bar for medtech developers everywhere. Staff writer Andrea Park and Editor-in-Chief Ayla Ellison discuss a few of the 15 startups that made the cut.  Plus, in this episode, we cover Illumina and Carl Icahn's proxy battle, Sanofi slashing insulin prices and more of this week's top headlines.  To learn more about the topics in this episode:  Fierce Medtech's 2022 Fierce 15 Illumina, Carl Icahn trade jabs amid looming proxy fight over $8B Grail buy Biogen, Novartis deliver one-two punch to Sangamo, walking away from deals in quick succession AbbVie's blockbuster-to-be Parkinson's combo hits a wall as FDA questions delivery pump Gilead's Yescarta puts pressure on BMS' Breyanzi with overall survival win in large B-cell lymphoma Selecta, Sobi rout gout in pair of phase 3 trials that could challenge Horizon Sanofi answers the call, joining Eli Lilly, Novo Nordisk in cutting insulin prices California invests $50M to partner with Civica Rx on insulin manufacturing The Top Line is produced by senior podcast producer Teresa Carey and managing editor Querida Anderson. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

California Governor Gavin Newsom announced on Saturday a 10-year partnership with nonprofit drug company Civica Rx to manufacture the state's own supply of insulin. Part of the state's new CalRx program, the move is only the first step in California's ambitious plan to produce more affordable generic prescription drugs — like overdose reversal medication naloxone — and make them available on the national market. We'll talk about CalRx and how it could help address the nation's drug affordability crisis. Guests: Angela Hart, senior correspondent covering health care politics and policy in California and the West, Kaiser Health News and California Healthline Kevin Wren, patient advocate and volunteer, California #insulin4all Robin Feldman, professor of law and Director of the Center for Innovation, UC Law; author of “Drugs, Money, and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices”

State of California Partners With Nonprofit Drugmaker To Produce Affordable Insulin   California Gov. Gavin Newsom has announced a $50 million, 10-year contract with nonprofit drugmaker Civica Rx to produce the state's own line of affordable insulin, CalRx, according to reporting from NPR and other sources. Upon FDA approval, these insulins, which are expected to be interchangeable with popular brand-name insulins, will be priced at no more than $30 per 10ml vial and $55 for a box of five pre-filled pen cartridges, potentially saving out-of-pocket patients up to $4,000 per year. The move is part of California's broader CalRx initiative to manufacture generic drugs under the state's label and disrupt the pharmaceutical industry, with plans to produce generic naloxone next.   Summary Factbox: What is the Willow project in Alaska, and why do green activists oppose it? | Reuters  People Are Dragging MrBeast For His Shoe Donation Video | BuzzFeed  New NPT Salary & Benefits Report Shows 6% Salary Hikes | The NonProfit Times    

State of California Partners With Nonprofit Drugmaker To Produce Affordable Insulin   California Gov. Gavin Newsom has announced a $50 million, 10-year contract with nonprofit drugmaker Civica Rx to produce the state's own line of affordable insulin, CalRx, according to reporting from NPR and other sources. Upon FDA approval, these insulins, which are expected to be interchangeable with popular brand-name insulins, will be priced at no more than $30 per 10ml vial and $55 for a box of five pre-filled pen cartridges, potentially saving out-of-pocket patients up to $4,000 per year. The move is part of California's broader CalRx initiative to manufacture generic drugs under the state's label and disrupt the pharmaceutical industry, with plans to produce generic naloxone next.   Summary Factbox: What is the Willow project in Alaska, and why do green activists oppose it? | Reuters  People Are Dragging MrBeast For His Shoe Donation Video | BuzzFeed  New NPT Salary & Benefits Report Shows 6% Salary Hikes | The NonProfit Times    

What The FTX Collapse Does & Does Not Mean For Crypto Philanthropy & Effective Altruism  Crypto-exchange FTX, one of the largest such exchanges, collapsed last week, leaving the cryptocurrency world in disbelief as stakeholders try to piece together what happened and what comes next. The company's founder Sam Bankman-Fried (known by the moniker SBF) was a visible proponent and donor to the effective altruism movement, as well as someone who built a personal brand as a prominent crypto-philanthropist. As noted by The New York Times, SBF was perhaps one of the most visible supporters of Effective Altruism, a community underpinned by a utilitarian approach to giving where donors focus on giving only to the most impact-efficient charitable causes. Created by Oxford philosopher William MacAskill, the Effective Altruism movement faces serious reputational trust issues as supporters worry it was a cover for the reckless FTX founder. It was also revealed by The New York Times that the two largest FTX Foundation grants went to nonprofits where MacAskill was on the board or directly supported the work of Effective Altruism. Bankman-Fried, who has also spoken frequently of his crypto giving, may have abused the crypto-philanthropy space to shield himself from questioning, but nonprofits should still understand that 38% of millennials own crypto and represent a major (and growing) potential source of donation revenue. (Editor's Note: The above link is a blog post written by Whole Whale CEO George Weiner, the publisher of this newsletter. The Giving Block is a proud partner and client of Whole Whale.) Read more ➝   Former executives of nonprofit indicted in alleged $10.7 million fraud scheme | KLBK California expected to partner with nonprofit Civica Rx to produce its own low-cost insulin, sources say | NBC News  New York City nonprofits stepping up to help asylum seekers find jobs | CBS New York    

Dan Liljenquist of Intermountain Healthcare Dan Liljenquist, Senior Vice President and Chief Strategy Officer for Intermountain Healthcare, discusses physician shortages, the economics of drug development and distribution, and his career path with and before Intermountain Healthcare. Value-based care isn't a destination; it's an evolution. Learn where Dan sees that evolution going next and how it has led to the creation of the nonprofit generic drug manufacturing company Civica Rx. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Dan Liljenquist, Senior Vice President and Chief Strategy Officer for Intermountain Healthcare, discusses physician shortages, the economics of drug development and distribution, and his career path with and before Intermountain Healthcare. Value-based care isn't a destination; it's an evolution. Learn where Dan sees that evolution going next and how it has led to the creation of the nonprofit generic drug manufacturing company Civica Rx.See omnystudio.com/listener for privacy information.

Meet Dan Liljenquist:Dan Liljenquist is the lead architect and Board Chair of Civica Rx. His also Senior Vice President and Chief Strategy Officer for Intermountain Healthcare, where he also oversees Intermountain's Enterprise Initiative and Market Intelligence & Planning Offices. Prior to Intermountain, Dan served in the Utah State Senate. He is a former strategy consultant with Bain & Company, Inc. Dan received a bachelor's in Economics from Brigham Young University and a JD from The University of Chicago.  Key Insights:Dan Liljenquist knew the pharmaceutical industry needed to change. He helped establish a nonprofit drug company to reduce generic drug shortages and price gouging. Market Forces. Huge price increases on generic drugs are only possible under certain market conditions: there is inelastic demand, economies of scale are necessary for manufacturing, and only one manufacturer is required to meet market demand. Public Utility. For some drugs there is essentially a monopoly. Dan set out to organize the demand side of the equation into a monopsony, a purchasing monopoly. CivicaRx was created to be a non-profit drug company that acts like a public utility, providing hospitals with a consistent and cheaper supply of certain drugs.Asking the Right Questions. Dan sought out experts and “badgered” them with questions. After extended discussion and iterations on the core hypothesis, the business model and vision emerged. Dan advises entrepreneurs to learn everything you can about what inspires you.This episode is hosted by Gary Bisbee, Ph.D. He is the Founder, Chairman, and CEO of Think Medium. Relevant Links:Learn more about CivicaRxRead “CivicaScriptTM Announces Launch of its First Product, Creating Significant Patient Savings”Read Dan's commentary on generic drug market issues, published in the New England Journal of Medicine

Meet Dan Liljenquist:Dan Liljenquist is the lead architect and Board Chair of Civica Rx. His also Senior Vice President and Chief Strategy Officer for Intermountain Healthcare, where he also oversees Intermountain's Enterprise Initiative and Market Intelligence & Planning Offices. Prior to Intermountain, Dan served in the Utah State Senate. He is a former strategy consultant with Bain & Company, Inc. Dan received a bachelor's in Economics from Brigham Young University and a JD from The University of Chicago.  Key Insights:Dan Liljenquist knew the pharmaceutical industry needed to change. He helped establish a nonprofit drug company to reduce generic drug shortages and price gouging. Market Forces. Huge price increases on generic drugs are only possible under certain market conditions: there is inelastic demand, economies of scale are necessary for manufacturing, and only one manufacturer is required to meet market demand. Changing Insulin. The price of insulin has gone up by an average of 11% a year for the past 20 years. CivicaRx will be bringing 3 insulin molecules to market, which collectively make up most of the insulin prescriptions in the U.S., for a retail price of no more than $30 per vile.Transparency. If Dan could change one aspect of the pharmaceutical industry it would be to make it more transparent. He points particularly to the confusing and opaque practices of pharmacy benefit managers and rebates. The high prices for pharmaceuticals have a real, negative impact on patients. Relevant Links: Learn more about CivicaRxRead “CivicaScriptTM Announces Launch of its First Product, Creating Significant Patient Savings”Read Dan's commentary on generic drug market issues, published in the New England Journal of Medicine

Drug shortages continue to be a major health care issue in the U.S., with more than 200 ongoing and active shortages per year since 2018. "Drug shortages are not new to health care," explains Dr. Mary Gilmer, director of pharmaceutical supply and procurement for Mayo locations across the Midwest. "But, really, over the last two years with the COVID-19 pandemic, the shortages have really exposed the vulnerability of our global drug supply chain. And these drug shortages remain high, despite decades of continued and increased awareness, effort and significant resource investment in these drug shortage programs at the highest level." At Mayo Clinic, the Pharmacy and Theruapuetics Committee has strategies and an organized approach to managing each drug shortage that's encountered."We engage our staff right down to the front-line team members when we're experiencing a shortage," says Dr. Gilmer. "When we place an order for a medication, and we do not receive sufficient quantities of what we're needing to take care of our patients, that's when we start escalating it, and really coordinating around how we understand and identify shortages so that we can best proactively manage them. So that's getting everybody on board for awareness, and any changes in our electronic health system that we need — or engaging our formulary colleagues to understand what alternatives or substitutes we can use." In addition to work done internally, Mayo Clinic also has taken a leadership role in combating drug shortages across the U.S., including joining the End Drug Shortages Alliance. The coalition is a collaboration of health system, supply chain and industry partners seeking to prevent drug shortages by solving pharmaceutical supply challenges and increasing transparency.Mayo was also a founding member of Civica Rx, a nonprofit generic drug company whose goal is to reduce shortages of essential medications that hospitals use. Civica Rx recently announced plans to manufacture and distribute affordable insulin. "We often talk about mitigating the impact of a drug shortage, but our goal is really to get further upstream and actually end them and stop them from happening,"says Dr. Eric Tichy, chair of the Division of Pharmacy Supply Solutions at Mayo Clinic. "So we do a lot of advocacy with the government and different regulatory agencies. And anytime someone says they want to help end or manage drug shortages, we're always interested in what that opportunity is."On the Mayo Clinic Q&A podcast, Drs. Gilmer and Tichy discuss Mayo Clinic's work to combat drug shortages.

Martin Van Trieste is the President and Chief Executive Officer, Civica Rx. Civica is making affordable insulin. Show notes for people who are Bold with Insulin Get your supplies from US MED with the link or 888-721-1514 Learn about the Dexcom CGM You may be eligible for a free 30 day supply of the Omnipod DASH  Get Gvoke Glucagon  Learn about Touched By Type 1 CONTOUR NEXT ONE smart meter and CONTOUR DIABETES app Tak the T1DExchange survey A full list of our sponsors  How to listen, disclaimer and more Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadioRadio Public, Amazon Music and all Android devices The show is now available as an Alexa skill. My type 1 diabetes parenting blog Arden's Day Listen to the Juicebox Podcast online Read my award winning memoir: Life Is Short, Laundry Is Eternal: Confessions of a Stay-At-Home Dad The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! Follow Scott on Social Media @ArdensDay @JuiceboxPodcast Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find the show and consider leaving a rating and review on iTunes. Thank you! Arden's Day and The Juicebox Podcast are not charitable organizations.

It's “In the News…” Got a few minutes? Get caught up! Our top stories this week include headlines from the ATTD Conference - that's the Advanced Technologies and Treatments for Diabetes Conference. There's a bit of new information about the Dexcom G7, Beta Bionics announces it will release pivotal trial results, and news of the first AID system using the Libre 3 is announced. Along with ATTD there's news about type 2 diabetes and grocery stores, all types of diabetes and nursing homes and a person with T1D is on the cover of British Vogue. Learn more about T1D Exchange here  Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX This week ATTD begins – that's the Advanced Technologies and Treatments for Diabetes Conference, so you can expect to hear a lot of news. I'll include some here, some next week and we've got future interviews lined up with a lot of the companies making headlines.. XX First up, a peek at more features in Dexcom's G7 system. It's approved in Europe but not the US and features what they're calling more meaningful alarms. You can silence more alarms, including urgent low & sensor fail for up to six hours, there's also a new 12 hour grace period at the end of the 10-day sensor life. It's already been announced the G7 has a much shorter warm up period, only half an hour, and is much smaller. -- Also at ATTD, Beta Bionics will be releasing Pivotal Trial Results of the iLet Bionic Pancreas. The iLet is a pump – connected to a CGM that is designed to autonomously determine and deliver insulin doses to control blood glucose levels. You'll recall this pump was originally designed to deliver both insulin and glucagon.. but the current iteration is insulin only. They says this pivotal trial population was more diverse and representative of the United States type 1 diabetes community than any previous pivotal trial of an automated insulin delivery system. We'll have more info on what these trials actually said next week. https://www.globenewswire.com/news-release/2022/04/25/2427846/0/en/Pivotal-Trial-Results-of-the-iLet-Bionic-Pancreas-To-Be-Presented-at-ATTD.html XX The first automated insulin delivery system using the FreeStyle Libre has been announced. This is in Europe and it's the Libre 3, Ypsomed pump and CamDiab software system. Expected by the end of the year, this is described as a self-learning app, a hybrid, closed-loop system that runs on an Android smartphone and can be tuned to users as young as one year old https://www.fiercebiotech.com/medtech/abbott-launches-diabetes-team-ypsomed-camdiab-bring-artificial-pancreas-system-europe XX And a new consensus meeting on Time in Range. In 2019, diaTribe formed the Time in Range Coalition, whose goal was to ensure that Time in Range (TIR) becomes the primary glucose metric for daily management, complemented by A1C, in diabetes care globally. But there isn't an internationally consensus on the use of CGMs in clinical trials. This meeting will help standardize those methods. XX Other highly anticipated – or at least well-publicized- studies coming to ATTD include those from Tandem and Omnipod and almost every big diabetes tech company. Lots more to come next week and we already have interviews set with Dexcom and Beta Bionics to we'll talk about all this in the long format episodes in weeks to come. XX Overtreating type 2 diabetes is apparently very common in nursing homes.. which can be a big problem as people get older and may require changes. New study in the Journal of the American Geriatric Society show about 40% of nursing home residents with type 2 diabetes may be overtreated. These researchers say one big issue is that at admission, residents are given a very big medical work up, but that isn't followed up on year to year. Often as people age, its recommended their A1C is maintained a bit higher, for safety reasons, so a target A1C could easily change years or even months after someone moves into assisted care or a nursing home. https://www.healio.com/news/endocrinology/20220422/diabetes-overtreatment-common-in-nursing-homes-with-little-medication-deintensification XX Right back to the news in a moment but first we've got a new sponsor. As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. Sign up at T1DExchange.org slash Stacey (that's S-T-A-C-E-Y). XX New survey looking at how people with diabetes rate their grocery stores. From D-Q&A this was a big survey, more than 5-thousand people statistically representative of all people with diabetes in the United States. They found more than half of people with diabetes did not feel very supported in maintaining their preferred eating habits at home. 28% of low-income people with diabetes find it somewhat or very challenging to find their preferred foods when grocery shopping. Stores rated best? Aldi, Publix, Costco, H-E-B, and Hyvee. The worst rated were BJ's, Vons, Shaw's, Ralphs, Tops & Randalls https://d-qa.com/major-grocery-chains-failing-to-meet-the-needs-of-people-with-diabetes/ XX Last year she made big news by walking the runway with her Omnipod visible, this year Lila Moss is – we think – the first person with type 1 on the cover of Vogue magazine. She did an interview with them that's on YouTube – I'll link up the video. She says she has an Apple air tag attached to her Pod PDM. Going through her handbag essentials, she included glucose tabs and talked about how her diabetes is something she doesn't keep hidden but just isn't always visible. Just nice to see a matter of fact interview featuring type 1. https://www.youtube.com/watch?v=5piEaumF6f0 XX On this week's long format episode, you'll hear from Civica RX – this is the company pledging to put out insulin without making a profit. We'll hear why they think this will work and how soon it'll be available for purchase. Next week we're talking about a new mental health conference for people with diabetes – it's virtual so you can participate from anywhere. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.  

Could this finally be a big shake up in the price of insulin? Civica Rx plans to sell the most popular types of fast and long acting insulin for a flat price of 30-dollars a vial. This week you'll hear from Ned McCoy, Civica's Chief Operating Officer. He explains why they're confident this will work, who will be able to buy the finished product, when it will be available and what Civica RX is all about. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's “In the News…” Got a few minutes? Get caught up! Our top stories this week include a new company called Luna Diabetes founded by some heavy-hitters in our community, a new #T1D telehealth study for underserved kids, improved life expectancy for people with type 2 and a look at 420 with diabetes. Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Our top story is a very interesting LinkedIn post about a new company and product.. Luna Diabetes aims to fill in a big gap – overnight automated control for people who use smart insulin pens. They're calling it A-I – automated injections, a way to combine the convenience of insulin pens with the clinical outcomes of automated insulin delivery – like Control IQ or Looping. Some heavy hitters here – the founders are John Show-lund Sjolund – founder of Timesulin, John Brilliant a co-founder of BigFoot biomedical and Sean Saint, founder of Companion Medical who made the InPen automated pen system. The release shows a little device but no real information yet. Is it an automated basal delivery system for overnights only? pivotal trial to start by the end of this year We'll keep you posted.. https://www.lunadiabetes.com/ XX A look at pediatrics in under-served communities shows most children are not meeting A1C goals. A new grant from the Helmsley Charitiable Trust will focus on expanding access through remote care. Many providers lack the money to set remote care up and use it effectively – telehealth systems and things like that. A large pediatric endo group in Buffalo, NY will work with Cecelia Health, a virtual first health care provider. They'll work with about a thousand patients to explore how improving access to remote support and the internet to better manage chronic conditions will improve outcomes. This is along with existing diabetes technology like pumps and CGMs. https://www.benzinga.com/pressreleases/22/04/n26682238/improving-outcomes-for-children-and-adolescents-living-with-type-1-diabetes-is-the-goal-of-a-colla XX Big news for people with diabetes in Australia. The government has committed to subsidized access to continuous glucose monitoring and flash glucose monitoring technology for all people living with type 1 diabetes. Right now, people under 21 are already eligible as as women who are actively planning a pregnancy or are pregnancy. This agreement will make everyone eligible for just over 30-dollars a month. Right now it costs over 300-dollars a month. I'm going to link up info from the incredible Diabetes Australia advocate Renza Scibilia who's been on the show before and who's been working on this for more than ten years. Congrats Renza and all who will benefit. https://www.diabetesaustralia.com.au/mediarelease/diabetes-australia-welcomes-bipartisan-commitment-to-cgmforall/ https://diabetogenic.blog/2022/04/17/oh-happy-day/ XX Not a big surprise but important information about improving life expectancy in people with type 2. New study shows reducing A1C, blood pressure, cholesterol and BMI makes a big difference. This was a University of Florida Gainesville study.. biggest improvement in all of these was reducing A1C from the highest in the study – about 9.9 - to the lowest about - 7.7 - added almost 4 years of life expectancy. These researchers say it's very motivating to patients and clinicians to see these gains and it may help them choose treatment goals. https://medicalxpress.com/news/2022-04-treatment-goals-diabetes-life.html XX We've talked about One Drop before.. more than a meter, they now call themselves a digital coaching company. And a new evaluation from an independent, third-party found that One Drop's support program effectively improves the health of people living with prediabetes, diabetes, and high blood pressure. The program could also cut down on annual healthcare costs. This is from the independent Validation Institute, dedicated to providing unbiased, data-driven insights on health care solutions. The Validation Institute financially guarantees the program's effectiveness. This means that people who follow the program properly but do not improve their blood pressure or A1C can file a claim with Validation Institute for up to $25,000. https://diatribe.org/one-drop-results-backed-by-independent-review XX Okay this newscast is going live on April 20th.. or 4-20.. There are a lot of questions about whether marijuana which is now legal in a lot of the US is okay to use if you have diabetes. I'm going to link up some information for you in the show notes.. But most of the information focuses on the slightly altered state weed can put you in.. for many that means being more relaxed but for some it may interfere with diabetes management in the moment. There's nothing specifically good or bad about marijuana that I could find for people with diabetes. However there is a warning for any pregnant woman -children who were exposed to cannabis in utero may be at risk for obesity and high blood sugar later in life. https://beyondtype2.org/marijuana-and-type-2-diabetes/ XX On this week's long format episode, Dr Mark Heyman is a diabetes psychologist who lives with type 1. He has great advice for the most under-treated part of diabetes, the mental health aspect of it all. Next week you'll hear from Civica RX – this is the company pledging to put out insulin without making a profit. We'll hear why they think this will work and how soon it'll be available for purchase. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Martin Van Trieste, BPharm, is the President and CEO of Civica Rx, which is a non-profit company whose mission is to ensure that essential generic medications are accessible and affordable. Civica Rx has partnered with health systems to reduce drug shortages and recently announced they will begin manufacturing insulin for release in 2024 that will cost no more than $30 per vial and no more than $55/box of 5 pen cartridges. Martin has been named one of the 100 most influential people in healthcare!https://civicarx.org 

It's “In the News…” Got a few minutes? Get caught up! Our top stories this week include new information about the temperature at which insulin can be safely stored, a warning about men taking Metformin, news about sexual health and women with diabetes, and a heads up about a virtual mental health conference coming up for people with diabetes. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Our top story.. a look at how insulin holds up under real-world and often hotter conditions than is recommended. Doctors without Borders found that a range of insulins can be stored at warmer temperatures than previously recommended. They showed it's okay above 77-degrees all the way up to 99 degrees for four weeks. This is really important not just for emergency settings like refugee camps but for people who live in areas without refrigeration. They often have to travel to health clinics which may be far away and which can't send them home with the insulin. The group now says pharmaceutical corporations should urgently submit to regulatory authorities for use of insulin under expanded temperature ranges. This came out a few weeks back, but I haven't seen it anywhere. https://www.doctorswithoutborders.org/latest/msf-study-shows-some-insulin-can-be-stored-warmer-temperatures XX Big headlines this week about Metformin and the risk of of birth defects in the babies of men who take it. Metformin is a very common diabetes drug, taken by tens of millions of people around the world. Sons born to men taking it were more than three times as likely to have a genital birth defect as unexposed babies. These problems were relatively rare, occurring in fewer than 1-percent of all babies with dads who took Metformin but it's significant because tens of millions of people worldwide take metformin. These researchers say the paper's findings are preliminary and observational only.. and that men with diabetes should NOT abruptly stop metformin before trying to conceive. Reassuringly, the researches saw no effect for men who took the drug earlier in life or even a year before. Expect a lot more research to come on this one. https://www.science.org/content/article/rare-genital-defects-seen-sons-men-taking-major-diabetes-drug XX Grain of salt needed here, but new research may show that people with type 1 are more likely to manage better if they have high levels of psychological resilience. This was a British study that followed 18-hundred people with type 1 or type 2 diabetes. They used a questionnaire to determine how they adapted to change and focused under pressure. The researchers found that people with type 1 diabetes who had low psychological resilience also had poorer blood sugar control after two years. The idea is that something like this would offer the opportunity to identify those who might benefit most from additional support when they are first diagnosed. https://medicalxpress.com/news/2022-03-psychological-resilience-future-high-blood.html XX Among patients with diabetes, women are just as likely as men to suffer from sexual dysfunction, but their issues are overlooked. Big session on this at the Diabetes UK Professional Conference this week. Reserachers say women with diabetes can experience reduced sexual desire, painful sex, and other issues which can increase the risk of depression. But these issues are usually untreated despite help being available. They talked about the embarrassment factor and the idea that many women with sexual dysfunction don't realize diabetes could be a factor. They encourage health care professionals to go beyond conversations about contraception, pregnancy and menstruation. A recent study led by Belgian researchers found that among more than 750 adults with diabetes 36% of men and 33% of women reported sexual dysfunction. https://www.medscape.com/viewarticle/971208 XX Concerning new trend about pre-diabetes.. it's doubled among children over the last 20 years. The increase was seen over almost all subpopulations of young Americans, regardless of income, ethnicity and education. The study in the journal JAMA Pedatirics included kids 12 to 19 years old from 1999 to 2018. The rate of presdiabetes went from 11.6-percent to 28.2-percent. Pre-diabetes means blood glucose levels are higher than normal but not yet at the diabetes threshold. These researchers are quick to point out, they don't know the reason why this is happening.. while diet and exercise are usually what's pointed to.. it's not entirely clear that's the reason behind this rise. https://www.cnn.com/2022/03/28/health/prediabetes-children-study-wellness/index.html XX Huge new study of more than 3-million people says people with type 2 have a higher risk of 57 other health conditions. Experts described the findings as stark and alarming and said it underlined the urgent need to reduce the risk of more people developing type 2 diabetes. The study, which is yet to be peer-reviewed, focused on people over 30. These researchers say the higher risks occurred when people were diagnosed with type 2 diabetes under the age of 50. https://www.theguardian.com/society/2022/mar/29/type-2-diabetes-results-higher-risk-57-other-conditions-study XX Want to let you know about the Diabetes plus Mental Health virtual conference coming up in May. This two-day event will highlight ways in which living with diabetes affects mental health. There will be 2 tracks - one for patients and one for caregivers and providers. I'm excited to take part – just in a light hearted way. I'll be hosting a game show type session where you can meet some of the presenters and participants. Lots more information lined up.. registration is open now and early bird pricing ends April 3rd. https://dmhconference.vfairs.com/?fbclid=IwAR2BiuxasHL0bBGe_6JpDzMnhY__kr6HptYFGpfdwEO0ftDL7pTbMyFycIY XX On this week's long format episode we're talking to JDRF about the new non-profit insulin they've backed. Why will this effort from Civica RX be different? We'll talk about it. Next week we'll have a conversation with one woman in the Joslin Medalist Study. Diagnosed nearly 70 years ago she shares her story and why she's excited about part of this incredible group. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

There's a new plan to manufacture and sell insulin at a much lower list price. The company behind it is non-profit Civica RX, which has support from JDRF. Stacey talks to JDRF CEO Aaron Kowalski about what their role is here, how realistic this plan is, who it may help and a lot more. They also spend some time talking about the reorganization of JDRF and what the future after COVID 19 looks like for them. More about Civica's Plan (we'll talk to them in a future episode) Here's the episode Stacey references with Thom Scher and Aaron Kowalski This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News..." Got a few minutes? Get caught up! Our top stories this week include increased risk of  type 2 after having COVID-19, CGM gets high marks as a telehealth device, Ypsomed pump picks a new partner, more study on the TB vaccine for type 1 and T1D: The Movie update! -- Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX People who recover from a mild case of COVID-19 appear to have an increased risk for subsequent new-onset type 2 diabetes… but not other types of diabetes. This is from a big new study in Germany. It lines up with previous studies of more seriously ill patients with COVID 19 who had increased rates of type 2 in the months following. This was more than 35-thousand patients – no prior history of diabetes. The risk of developing type 2 increased by 28-percent if the person had COVID, again even a mild case. The researchers say anyone who tested positive for COVID should be aware and get screened for diabetes in the months and years following. https://www.medscape.com/viewarticle/970600 XX Big new study that – interestingly – talks about the CGM as a telehealth device. It looked at how doctors continued to care for children with type 1 before and after the first year of the COVID pandemic. The use of CGMs increased significantly among those with non-commercial insurance… from 24 percent in 2019 to 35 percent by the end of 2020. Another finding in this same study.. those with higher A1Cs, racial minorities, and those with non-commercial insurance were more likely to have high rates of DKA. But the implementation of telehealth and CGMs increased parental oversight which resulted in better care at home and lower than expected hospitalization rates. I want to dig a little deeper here because a lower hospitalization rate during the first year of the COVID pandemic overall.. was found to be tied to a lot of fear about going to a hospital during that time. https://mhealthintelligence.com/news/telehealth-helped-maintain-type-1-diabetes-care-among-kids-during-pandemic XX Swiss pump maker Ypsomed announces the software they'll use for their automated insulin delivery. Ypsomed will partner with CamDiab's CamAPS app. The launch will start in select major countries in Europe, with other territories to follow over the course of 2022. This includes a hybrid closed loop – like Omnipod 5 and Control IQ - as well as smartphone control.. it's compatible with Dexcom's G6. It'll start on Android then roll out on iOS.. Ypsomed is partnering with Lilly to come to the US – we've had them on the show before talking about this. They hope to submit to the FDA this year. https://www.drugdeliverybusiness.com/ypsomed-partners-with-camdiab-on-smartphone-based-automated-insulin-delivery/ XX The FDA is due to make a decision on Teplizumab by August 17th. This is a drug that has been shown to delay type 1 diabetes. Last year the FDA turned down Provention Bio, asking for a resubmission with more information. The company is also running the phase 3 PROTECT trial of teplizumab. That's in newly-diagnosed type 1 diabetes patients. They hope to expanding the indications for the drug. https://pharmaphorum.com/news/fda-sets-august-decision-date-for-proventions-type-1-diabetes-drug/ XX More study underway into the tuberculosis vaccine as a treatment for type 1. This is Dr. Denise Faustman's lab – they're recruiting 150 teen with type 1 for pediatric clinical trials of the shots. Faustman's work is controversial because her studies have been very small and many experts say they don't show significant improvement. But Faustman says the vaccine appears to help patients with Type 1 diabetes by altering their immune system and that even though no one in her trials is off of insulin, there is improvement. https://www.bostonglobe.com/2022/03/21/metro/could-100-year-old-vaccine-treat-type-1-diabetes-mgh-researchers-are-working-find-out/ XX If you're watching live, today is the last day to back the Kickstarter for Type 1 The Movie. We talked about this on last week's podcast episode – Noah Averbach Katz is an actor who lives with type 1 and is making a movie where diabetes is front and center. Since Noah and his wife are on Star Trek Discovery, that community has jumped in to really amplify this. It's been great to see and he's well over his goal. If you're watching or hearing this after March 23rd, you can follow the link anyway to stay up to date on the project. I gave and I'm excited to see how it all turns out! https://www.kickstarter.com/projects/noahak/type-1?ref=thanks-tweet XX On this week's long format episode we're going on a deep dive about stem cell research with the folks at Viactye. They're working on two fronts now.. encapsulation AND gene editing with the people at CRISPR. Next week you'll hear from JDRF about the new non-profit insulin they've backed. Why will this effort from Civica RX be different? We'll talk about it. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

It's “In the News…” Got a few minutes? Get caught up! Top stories this week: Dexcom G7 approved in Europe, JDRF speaks out on non-profit insulin plan, Ukraine diabetes aid progress, texting for T2D, Reaction to Pixar's Turning Red -- Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Our top story this week.. Dexcom gets the CE Mark for it's new G7 system, which means it's approved in Europe. The approval is for people ages 2 and up, including pregnant women. I'm putting the full screen photo up here and I'll post this on the website and in the FB group for those listening.. interesting to finally get a good look at the much smaller applicator – as expected looks a lot like the Libre. Also interesting, all the PR for this has said, developed in partnership with Verily.. remember them? That was part of google, probably best known for saying they were going to develop a contact lens that would monitor glucose. I've reached out to Verily, love to know more about this partnership. Anyway, we've done a ton on G7, I'll link up some of our recent conversations with the folks at Dexcom. They submitted to the US FDA at the end of 2021, no firm timeline on US approval. https://www.medicaldevice-network.com/news/dexcom-ce-mark-g7-cgm-system/ XX Some good news about living longer with chronic conditions, including diabetes. This was a 20-year British study that ended in 2011, so one caveat here, it doesn't include COVID. Men gained 4-point-6 years of life expectancy; women gained 2-point-1. When it comes to disability-free life expectancy, men gained about a year less and women stayed the same. This included people with chronic conditions including those with diabetes. These researchers do point out that while they'd expect to see the same increase in the US – the lack of health and social safety net programs could make a negative difference here. But they point to CGM technology and better medication as making a big difference for those with diabetes. https://www.healthline.com/health-news/why-people-with-chronic-conditions-such-as-diabetes-are-living-longer-without-disability#Cognitive-impairment-is-the-exception XX Children who develop type 1 diabetes show epi-genetic changes in the cells of their immune system long before the antibodies of the disease are detected in their blood. An epigenetic change affects how our genes work. Outside factors such as environmental, viral infections, are usually the cause. These researchers say these are previously unknown changes that signal the increased risk of developing type 1 and could give an even earlier indication than the anti-body marker tests available now. https://www.news-medical.net/news/20220316/Epigenetic-changes-could-be-a-biomarker-for-early-detection-of-type-1-diabetes.aspx XX Could text-messaging with their doctors help people with type 2? A new team in Chicago is looking at text-based intervention in underserved communities. The intervention will deliver personalized information directly to patients through text messages, including reminders about self-monitoring and prescription refills, interactive office hours and general information about diabetes, motivational support and answers to frequently asked questions. These doctors say the idea is to create more opportunities for patients to meaningfully engage and reduce barriers by employing technology already in people's hands. https://today.uic.edu/an-sms-solution-for-type-2-diabetes XX Last week we told you about the effort by Civica RX to make affordable insulin. Civica, is a nonprofit generic pharmaceutical company. JDRF directed funds to this effort and CEO Aaron Kowalski wrote an op ed that I'll link up. In it, he talks about the success Civica has had lowering the costs of other medications. We'll have Kowalski on the show soon and I've reached out to Civica as well. This would lower the price to $35 a vial no matter your insurance. Congress still hung on a $35 co-pay cap for those with insurance. https://www.healthline.com/diabetesmine/op-ed-jdrf-leader-on-insulin-affordability-for-all-americans XX Over in the UK they keep moving forward – covering all 400-thousand Britons with type 1 for the Libre CGM. Former guest of the podcast, Dr. Partha Kar, says everyone with type 1 will be able to get a CGM if they want one by the end of March. It will no longer be restricted by who doctors think need it the most. By the way, Briton means someone from England, Scotland or Wales. It's the first time I'm using that word so UK friends.. let me know if I've got it right! https://www.dailymail.co.uk/health/article-10606335/All-400-000-type-1-diabetic-Britons-offered-high-tech-implant.html XX Still a big need for diabetes help to Ukraine. A lot of the efforts are paying off – Insulin for Life showing that the supplies are on their way or have arrived. Spare a Rose reports that individual donations so far have totaled more than 115-thousand-dollars. I'll keep linking up places to donate https://www.jdrf.org/blog/2022/03/02/helping-the-diabetes-community-in-ukraine/ XX Reaction to Pixar's Turning Red. I loved this. I put out a call for photos of people seeing themselves in the movie's tiny little moments of diabetes representation. Thanks to all who sent those in – you can see them on Diabetes Connections on Facebook and Twitter. And my Stacey Simms account on Instagram. It's all just one account there. XX While Turning Red had diabetes in the background.. this week on the long format episode we're talking about a movie that wants to put type 1 front and center. And it's got the Star Trek community excited as well! Meet the Star Trek Discovery actor with type 1 who's leading this effort. Next week, we're going on a deep dive about stem cell research with the folks at Viactye. They're working on two fronts now.. encapsulation AND gene editing with the people at CRISPR. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.  

Civica Rx to manufacture and distribute affordable insulin. JDRF CEO Aaron Kowalski is here to discuss the news. Show notes for people who are Bold with Insulin Learn about the Dexcom CGM You may be eligible for a free 30 day supply of the Omnipod DASH  Get Gvoke Glucagon  Learn about Touched By Type 1 CONTOUR NEXT ONE smart meter and CONTOUR DIABETES app Tak the T1DExchange survey A full list of our sponsors  How to listen, disclaimer and more Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadioRadio Public, Amazon Music and all Android devices The show is now available as an Alexa skill. My type 1 diabetes parenting blog Arden's Day Listen to the Juicebox Podcast online Read my award winning memoir: Life Is Short, Laundry Is Eternal: Confessions of a Stay-At-Home Dad The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! Follow Scott on Social Media @ArdensDay @JuiceboxPodcast Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find the show and consider leaving a rating and review on iTunes. Thank you! Arden's Day and The Juicebox Podcast are not charitable organizations.

Civica, Inc. (Civica, Civica Rx) announced plans to manufacture and distribute insulins that, once approved, will be available to people with diabetes at significantly lower prices than insulins currently on the market.  Dan Liljenquist, Board Chair of Civica Rx and Intermountain Healthcare Chief Strategy Officer​ calls in to explain what this is and when we will see it become available  See omnystudio.com/listener for privacy information.

It’s the end of the week, and we’re settling in for Economics on Tap! We’ll close the loop on some questions we raised earlier about the Federal Reserve and swap lines and explore a story on a group of hospitals teaming up to bring affordable insulin to patients. And of course, a round of the game we’re all here for — Half Full/Half Empty! Our hosts offer their thoughts on the State of the Union speech, dynamic pricing for “The Batman,” Hollywood’s silver screen obsession with Uber and Theranos, and a “Reading Rainbow” reboot! Here’s everything we talked about on the show today: “U.S. Funding Markets Show Signs of Stability Despite Russia Sanctions” from The Wall Street Journal Cheap insulin for diabetics is next mission for Civica Rx nonprofit drug maker from The Washington Post Guy Reffitt’s Son Testifies Against Him in Jan. 6 Trial from The New York Times James Fallows: Biden’s State of the Union, Annotated from The Atlantic AMC Charges More for “The Batman” Tickets, Like Spielberg Predicted from Variety “IRS aims to hire 10,000 workers to reduce crippling mail backlog” from Politico “The Dropout” and “Super Pumped” chronicle the fall of Theranos, rise of Uber and the human cost of tech greed from the Washington Post “‘Reading Rainbow’ is getting a reboot but without LeVar Burton” from NPR Give today to support Make Me Smart.

It’s the end of the week, and we’re settling in for Economics on Tap! We’ll close the loop on some questions we raised earlier about the Federal Reserve and swap lines and explore a story on a group of hospitals teaming up to bring affordable insulin to patients. And of course, a round of the game we’re all here for — Half Full/Half Empty! Our hosts offer their thoughts on the State of the Union speech, dynamic pricing for “The Batman,” Hollywood’s silver screen obsession with Uber and Theranos, and a “Reading Rainbow” reboot! Here’s everything we talked about on the show today: “U.S. Funding Markets Show Signs of Stability Despite Russia Sanctions” from The Wall Street Journal Cheap insulin for diabetics is next mission for Civica Rx nonprofit drug maker from The Washington Post Guy Reffitt’s Son Testifies Against Him in Jan. 6 Trial from The New York Times James Fallows: Biden’s State of the Union, Annotated from The Atlantic AMC Charges More for “The Batman” Tickets, Like Spielberg Predicted from Variety “IRS aims to hire 10,000 workers to reduce crippling mail backlog” from Politico “The Dropout” and “Super Pumped” chronicle the fall of Theranos, rise of Uber and the human cost of tech greed from the Washington Post “‘Reading Rainbow’ is getting a reboot but without LeVar Burton” from NPR Give today to support Make Me Smart.

Healthcare is scaling digital through partnerships. FTA Graphite Health, a member-led company intent on transforming digital health care to improve patient outcomes and lower costs, launched today and announced its first three organizing members, https://www.ssmhealth.com/ (SSM Health), https://www.phs.org/Pages/default.aspx (Presbyterian Healthcare Services), and https://intermountainhealthcare.org/ (Intermountain Healthcare). Modeled on https://civicarx.org/ (Civica Rx), a https://catalyst.nejm.org/doi/full/10.1056/CAT.21.0189 (health utility company), Graphite Health will focus on health care interoperability challenges. Building on a common data language, Graphite Health is creating a standardized, interoperable data platform that enables a secure and open marketplace to streamline the distribution of digital health solutions for both health systems and entrepreneurs. For entrepreneurs, the common data language addresses inefficiencies in data translation and supports the development of plug-and-play digital applications. In turn, health system members can implement trusted digital tools as easily as anyone can download an app from an app store to a smartphone. These improvements will lead to more convenience, better quality care, lower costs, and overall efficiency. ____ This is a very real problem. The app store for healthcare has been talked about since Steve Jobs stood on a stage all those years ago and made "app store" a common term for everyone. Graphite is solving the right problem with an interesting business model. I'm excited to see where this one goes. #healthcare #cio #healthIT #cmio #chime #himss https://www.graphitehealth.io/whats-new/#comp-km2ijxtz (https://www.graphitehealth.io/whats-new/#comp-km2ijxtz)

I spoke with Erin Fox, Senior Director at University of Utah Health, about the future direction of the #pharmaceutical industry and the changing role of #pharmacists. We will discuss everything from #drugshortages to on-shoring, #cybersecurity to Civica Rx and much much more.

In this episode, Back in America’s host, Stan Berteloot speaks with Navi Radjou, internationally renowned Indian-French-American scholar, innovation and leadership advisor, and bestselling author based in New York. Navi’s most recent book, Frugal Innovation: How To Do More With Less, shows how companies can innovate faster, better, and more sustainably.  The conversation focuses on Navi’s work on developing an alternative to capitalism and concrete actions individuals and businesses are taking to build a better, more sustainable world. “My job is to introduce Americans to new ways of doing business, new ways of creating economic and social value in a sustainable way,” says Radjou.  He describes the “frugal economy” as a new economy that is built on business-to-business (b2b) sharing, local production from micro-factories, the notion of regeneration, or how companies can consciously have a positive impact on society and the planet. Since Navi is multicultural, the episode focuses on the values, culture, and identity of America. Navi comments on an excerpt from a previous Back in America interview with American writer and thinker John Michael Greer.  In the audio clip, we hear Greer say that America is all about independence and every man for himself, while European countries have a more communal attitude. In response, Navi asked: “Why do we have to choose? Why can we have both? Why can we go into a kind of the third dimension where we try to integrate the goodness of America, the goodness of Europe? The ideal society,” he says, “is the one that tried to find the sweet spot between maximizing individual expression while contributing to social integration.” Navi backs up his theories with concrete examples of companies, such as Xometry, People + Work Connect from Accenture, Unilever, Civica RX, or Convoy that are currently working according to the frugal economy precept. Here are two of Radjou’s articles on Frugal Economy and B2B Sharing : The Rising Frugal Economy The sharing economy’s next target: Business-to-business Navi Radjou’s Movie and Books Selection The Evolving Self: A Psychology for the Third Millennium Paperback  by Mihaly Csikszentmihalyi  The Life Divine Paperback  by Sri Aurobindo Movie Losers on Netflix    Watch the full, unedited, interview on YouTube

Ira Pastor, ideaXme life sciences ambassador, interviews Daniel Liljenquist, former US Senator and Lead Architect and Board Chair of Civica Rx. Ira Pastor Comments: A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents, and are typically allowed for sale after the patents on the original drugs expire. Once generic drugs enter the market, competition often leads to substantially lower prices for both the original brand-name product and its generic equivalents. In 2014, according to an analysis by the Generic Pharmaceutical Association, generic drugs accounted for 88% of the 4.3 billion prescriptions filled in the United States, and the use of generic drugs in the United States led to US$254 billion in health care savings. The global market for generic drugs is estimated to reach $533 billion by 2021, up from $352 billion in 2016, and was growing at a compound annual growth rate (CAGR) of 8.7% during that period. Unfortunately, in recent years things have been amiss in the generics drug segment whereby we have been seeing a rapid rise in the prices for many generic drugs that have been around for many years, if not decades.There has been major consolidation, with a handful of major companies dominating the generic drugs market (some units of big pharma), and there is an estimated backlog of 000s of generic drugs awaiting FDA approval. All of these factors have played a role in how both rare and common drugs, such as EpiPens, can shoot up in price so rapidly. Daniel Liljenquist: Mr. Daniel Liljenquistis an American businessman and politician, who served in the Utah State Senate, and is the Lead Architect and Board Chair of Civica Rx,a nonprofit generic drug company established to reduce chronic generic drug shortages and price gauging. Dan also serves as Senior Vice President and Chief Strategy Officer for Intermountain Healthcare (a not-for-profit healthcare system that is the largest healthcare provider in the Intermountain West region of the United States, provides hospital and other medical services in Utah, Idaho, and Nevada, and has 37,000 employees) where he oversees Intermountain’s Enterprise Initiative and Market Intelligence & Planning Offices. Intermountain was one of the founding groups behind Civica Rx. Dan has degrees in Economics from Brigham Young University, and Law from University of Chicago Law School. On this ideaXme episode we will hear from Dan about: His background and his personal journey through the world of economics, law, and politics, and into the world of non-profit healthcare cost containment. The background story leading up to the decision of the formation of Civica Rx. Civica Rx's development from start-up in 2018, to a robust network of 45 health systems, representing 1200 hospitals, with a total of 18 medications in production. Civica Rx's plans to bring over 100 medications to market in the next five years and building its own manufacturing capability. Civica Rx's partnerships on the international manufacturing and regulatory fronts. Credits: Ira Pastor interview video, text, and audio. Follow Ira Pastor on Twitter:@IraSamuelPastor If you liked this interview, be sure to check out ourinterview about Ibogaine therapies! Follow ideaXme on Twitter:@ideaxm On Instagram:@ideaxme Find ideaXme across the internet including on iTunes, SoundCloud,Radio Public,TuneIn Radio,I Heart Radio, Google Podcasts, Spotify, Amazon Podcasts and more. ideaXme is a global podcast, creator series and mentor programme. Our mission: Move the human story forward!™ ideaXme Ltd.

I hope you’re enjoying our fascinating ‘You Won’t Believe What We’ve Seen’ mini-series, in partnership with SQA services. In last week’s episode ‘Mission Control’ (insert link), we talked to SQA founder and President Mike McKay, and industry professional and advisor to SQA Jeff Luckey, and delved into the incredible world of aircraft and aerospace. And we have an equally amazing podcast for you today, with episode 2 ‘Saving Lives,’ as we dive into the life sciences. Mike McKay joins us once again, alongside President & CEO of Civica Rx Martin Van Trieste, one of Modern Healthcare’s ‘100 Most Influential People in Healthcare’ and the #2 leader on The Medicine Maker’s ‘Power List of Industry Influencers.’ They’re going to be exploring the dark world of counterfeit drugs and shadow factories, sharing their passions and experiences after many years at the top of their industry, and reinforcing that all-important topic of Quality. You don’t want to miss it! IN THIS EPISODE WE DISCUSS: [00.58] Introducing Mike McKay. [02.18] Introducing Martin Van Trieste. [04.28] SQA’s key partnerships in the life sciences industry, from Pfizer to Johnson and Johnson. [05.01] Martin’s long-standing relationship with SQA, and why he came to rely on their services. “Over 20 years, I’ve become enamored with their business model. But more importantly, I grew to respect Mike and his team so much – I trust them – and that’s something that takes a long time to build.” (MVT) [07.15] The importance of working as an extension of a customer’s team, being flexible, efficient and meeting customized needs. [10.21] How saving time and money through using a team of specialists like SQA, means customers are freed up to work on the important things – saving lives. [12.02] Why working with SQA is not simple out-sourcing: it’s all about information sharing, communication, honesty and collaboration. “It’s a very interactive process.” (MVT) [14.27] Shadow factories, their impact on the industry, and on saving lives. [16.52] Show factories, and Mike’s eye-opening industry experiences. “Our auditor walked over to a drum, lifted up the top and saw the laminate still inside – no product had been made there!” (MMK) [19.12] Supply and demand during COVID-19. [23.15] SQA’s passion and pride to be doing their part in developing vaccines and saving lives. [26.06] Why there are drug shortages, ‘Just in Time’ vs ‘Just in Case’ and how/why Martin’s company Civica Rx are moving towards shorter, more robust supply chains. “Not all industries are the same: you can’t apply every solution to the same problem in a different industry.” (MVT) [31.45] Why quality is so important, both on a business and a personal level. [33.41] How SQA’s ‘Quality Is’ campaign helps to keep quality at the top of everybody’s agenda, both internally and with customers too. [35.53] Why without quality, you don’t have safety – and you can’t save lives. You can connect with Mike on LinkedIn, or head over to SQA’s website now to find out more, meet the team and discover how they could help you too. You can also connect with Martin on LinkedIn or find out more about Civica Rx's pioneering work on their website. Check out our other podcasts HERE.

Martin VanTrieste is the President and CEO of Civica Rx, a groundbreaking, non-profit pharmaceutical company that's innovatively working to address our nation's generic drug shortages.  For years, our domestic drug manufacturing and supply chains have eroded, resulting in shortages of anesthetics, antibiotics, cancer drugs, even sterile IV fluids necessary for delivering nearly every drug used in a surgical setting.  Martin, who was recently named one of Modern Healthcare's 100 Most Influential People in Healthcare, is working at the cutting edge with his team at Civica to make drug shortages a thing of the past. Visit A Second Opinion's website here: https://asecondopinionpodcast.com/ Engage with us on social media at: Facebook Twitter Instagram

Martin VanTrieste of Civica RX on generic drugs. Isaac Weiner of The Ohio State Univ and Amy DeRogatis of Michigan State on the American Religious Sounds Project. Vince Beiser on "The World in a Grain: The Story of Sand and How it Transformed Civilization." Heide Lukosch of the Univ of Canterbury on games and disasters. Andy Davis of Univ of Georgia on monarch butterflies in captivity. Cheedy Jaja of the Univ of South Carolina on trauma and healthcare workers.

Marc Harrison, M.D., president and CEO of Intermountain Healthcare, is a pediatric critical care physician with a proven track record as a top operations executive on a global scale. He is a national and international thought leader on transformation and innovation—ranking in Fortune Magazine’s Top 50 World’s Greatest Leaders in 2019. He also ranked second among Modern Healthcare’s Most Influential Physician Executives and Leaders and tied for second on its list of the 100 Most Influential People in Healthcare in 2018. Dr. Harrison embraces strategic partnerships and novel collaborations to solve systemic problems and improve lives. Together with Intermountain’s 38,000 employees —who are all called caregivers—he has implemented bold new approaches to improve health, re-define value-based care, and serve people in new ways. Intermountain’s partnerships, pioneering initiatives, and commitment to service are transforming healthcare and bearing fruit for patients and communities. For example, Intermountain led a partnership of hundreds of hospitals to launch Civica Rx, a not-for-profit generic drug manufacturer and distributor, to make generic medications more available and affordable in hospitals across the nation. Intermountain is also a founding member of the Utah Alliance for the Determinants of Health, which is a collaboration of community partners designed to proactively address forces that affect people’s health well before they come to a clinic or a hospital. Previously, Dr. Harrison served as CEO of Cleveland Clinic Abu Dhabi, chief of international business development at Cleveland Clinic, and chief medical operations officer. He received his undergraduate degree from Haverford College, his medical degree from Dartmouth Medical School, completed a pediatric residency and pediatric care fellowship at Intermountain’s Primary Children’s Hospital, and a Master of Medical Management at Carnegie Mellon University. Dr. Harrison is an all-American triathlete and represented the U.S. at the 2014 World Championships.

Donald Stinson, author of “Downstairs at the White House,” on working at the White House. Dan Liljenquist of Intermountain Healthcare and Civica Rx on generic drugs. Douglas Eck, Google, on A.I. Music. Ivonne Roman of the Women’s Leadership Academy on policewomen. Viktor Mayer-Schönberger of Oxford Univ on forgetting digital memories.

House Speaker Nancy Pelosi compromises with progressive democrats on drug pricing legislation ahead of a vote. Civica Rx announces it will have eight generic drugs shipped by the end of the year. For the first time, female medical students are the majority.

Listen NowOn October 31st, the FDA released the agency's Congressionally-mandated report titled, “Drug Shortages: Root Causes and Potential Solutions.”  The 124-pg report found drug shortages are increasing, persistent, i.e., the duration longer, with both the intensity and public health impact high.  These shortages can, the FDA found, “have a devastating effect,” by prolonging patient suffering, contributing to disease progression & increased morbidity.  Concerning root causes, the FDA found market consolidation has caused current contracting practices to constitute in sum a “race to the bottom.”   The FDA also found the market also fails to recognize or reward manufacturers for mature quality management systems and found a market that is unable to quickly recover after a disruption in either manufacturing or supply chain distribution.  Despite the worsening drug shortage problem, and the Congress' considerable focus on drug pricing legislation this year, not a single drug shortage committee hearing was held this Congressional session or this year.  (Listeners may recall I posted in August a related essay I wrote on this topic for STAT).  During this 28 minute conversation Captain Jensen begins by providing an overview of her day to day efforts managing the FDA's drug shortage efforts.  She moreover discusses the details of the FDA's report to the Congress, principally the report's recommendations, potential other related solutions including improving risk management planning, stockpiling and lengthen expiration dates, efforts by Civica Rx and Provide GX,  forthcoming FDA drug shortage guidances and potential for Congressional action. Captain Valerie Jensen is the Associate Director of the Drug Shortage Staff at the Food and Drug Administration.  She previously worked as a clinical pharmacist for Indian Health Service hospitals in Arizona and New Mexico for nine years before joining FDA.  She has been with the FDA for the past 19 years leading FDA efforts to work with manufacturers to mitigate and resolve shortages of medications for the patients who depend on them.  Captain Jensen received a B.S. degree in Pharmacy from the University of Iowa in 1990 and upon graduation was commissioned as an officer in the U.S. Public Health Service.  She completed an American Society of Health-System Pharmacists Specialized Residency in Ambulatory Care at the White River Indian Health Service hospital in White River, Arizona in 1991. The FDA's report is at: https://www.fda.gov/drugs/drug-shortages/report-drug-shortages-root-causes-and-potential-solutionsA related and recent Civica Rx report is at: https://civicarx.org/wp-content/uploads/2019/10/Civica-Rx-White-Paper-FINAL-10.01.19-1.pdfAgain, my related August STAT essay is at: https://www.statnews.com/2019/08/09/drug-shortages-presidential-candidates-policy/(In my opening statement, I misspoke.  The drug shortage problem adds at least approximately over half a billion (not half a million), dollars annually to healthcare spending.)   This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thehealthcarepolicypodcast.com

In this week’s Our Take, we’re covering the proposed rules to ease restrictions imposed by Stark Law, anti-kickback statute. To sign up for the weekly email brief, click here. Other briefs include:Dartmouth-Hitchcock Health and GraniteOne Health signed an agreement to merge.Walmart is testing new health benefits to help employees receive appropriate care.ICER pulled a draft evidence report it released in late September on three new rheumatoid arthritis drugs.UPS is set to expand its drone delivery service to hospital campuses nationwide.Civica Rx’s first drug has been administered to patients.Dr. Patrick Conway has stepped down as CEO of Blue Cross Blue Shield of North Carolina. About Darwin Research GroupDarwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

In this week’s Our Take, we’re covering the latest results from the Medicare Shared Savings Program ACO data, just released last week. To sign up for the weekly email brief, click here. Other briefs include:Dartmouth-Hitchcock Health and GraniteOne Health signed an agreement to merge.Walmart is testing new health benefits to help employees receive appropriate care.ICER pulled a draft evidence report it released in late September on three new rheumatoid arthritis drugs.UPS is set to expand its drone delivery service to hospital campuses nationwide.Civica Rx’s first drug has been administered to patients.Dr. Patrick Conway has stepped down as CEO of Blue Cross Blue Shield of North Carolina. About Darwin Research GroupDarwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

In today’s Our Take read-in, we discuss a bipartisan bill to lower drug prices that cleared a Senate committee. On Thursday, the Senate Finance Committee voted 19-9 to advance a bill proposed by Sens. Chuck Grassley, R-Iowa, and Ron Wyden, D-Ore., that includes numerous provisions to lower drug prices. The bill, called the Prescription Drug Pricing Reduction Act (PDPRA) of 2019, is likely to undergo considerable changes before it reaches the Senate floor for a full vote — if it gets that far. Over the span of a decade, the PDPRA as it currently stands would save $85 billion in Medicare spending and another $15 billion in Medicaid spending. Further, the Congressional Budget Office estimated that Medicare beneficiaries would save $27 billion in out-of-pocket costs and $5 billion in premiums during that same time period. Other briefs include: New research on ACOs with two-sided risk suggests lower costs and improved health outcomes. Tenet Healthcare Corp. is spinning off its Conifer business unit. CVS is testing a coordinated care pilot for Aetna beneficiaries requiring knee replacements. Civica Rx signs a five-year agreement with London-based Hikma, a generic drug manufacturer. Advocate Aurora Health names former Advocate CEO Jim Skogsbergh as president and CEO. Paula Steiner leaves her post as CEO of Health Care Services Corp. CVS Health names Dr. Sree Chaguturu as chief medical officer for CVS Caremark. Dr. Reshma Kewalramani is being elevated to CEO of Vertex Pharmaceuticals. About Darwin Research Group Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

Continued rising drug prices, as well as shortages for many critical medications, are impacting patient care and putting strains on hospital budgets and operations. That’s why hospitals and health systems have gathered to create Civica Rx, a not-for-profit generic drug company that is disrupting the pharmaceutical market. Chip spoke with Martin VanTrieste, Civica’s President & CEO about why and how the company was formed, the success it is enjoying so far, and if other drug companies will follow its lead. EPISODE UPDATE, Since our recording VIZIENT has announced it will collaborate with Civica to help reduce chronic drug shortages by providing insights into purchasing patterns and provider needs. Vizient will apply its expertise in analytics and data capabilities, helping Civica anticipate gaps in drug availability and affordability. In response to Vizient’s commitment, Civica’s VanTrieste said, “The more people collaborating to solve the nation’s drug shortage problem the better…we applaud Vizient for prioritizing hospital patients by taking action to help them have timely access to the treatments they desperately need on a day-to-day basis.”

In this week’s episode, John talks about the latest bombshell lawsuit filed by 44 states accusing Teva and other generic drugmakers of price fixing. Other briefs include: A house bill introduced to address surprise medical billing. CMS’ guidance designed to eliminate spread pricing. Advent International to acquire AccentCare. Civica Rx announces first two drugs in production. A hearing is set to review CVS-Aetna merger. About Darwin Research Group Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

Civica Rx is the brainchild of hospitals and health systems that formed a collaborative to hold down the spiraling costs of essential generic drugs. How is the plan working out? Civica Rx President and CEO Martin VanTrieste shares an update on the organization’s efforts on a new AHA Advancing Health podcast.

This week on the podcast, we're speaking with Civica Rx’s Heather Wall. She’s the organization’s chief commercial officer, and was recently named one of Modern Heatlhcare’s women leaders to watch.

For years, private companies have set the price of generic drugs at skyrocketing levels and created shortages to increase their demand and profit. But, a group of healthcare systems and philanthropies from across the country have now created the first non-profit company to manufacture and address the shortages and high prices of life saving medications. Intermountain Healthcare's Chief Strategy Officer Dan Liljenquist joins FM100.3's Rebecca Cressman to explain how Civica Rx will help ensure that patients have access to the medications they need at a fraction of their current costs.

This week, hosts Mark Masselli and Margaret Flinter speak with Shelley Lyford, CEO of the Gary and Mary West Foundation which is dedicated to reducing costs and improving care for America’s seniors. She discusses the launch of Civica Rx – a not for profit entity that will supply low-cost generic drugs to a consortium of partner foundations and hospitals to disrupt monopolies and price gouging in the pharmaceutical industry. The post Disrupting the Generic Drug Market: Gary and Mary West Foundation CEO Shelley Lyford on Civica Rx Launch appeared first on Healthy Communities Online.

Today in FirstWord:

Drug shortages continue to be a major health care issue in the U.S., with more than 200 ongoing and active shortages per year since 2018. "Drug shortages are not new to health care," explains Dr. Mary Gilmer, director of pharmaceutical supply and procurement for Mayo locations across the Midwest. "But, really, over the last two years with the COVID-19 pandemic, the shortages have really exposed the vulnerability of our global drug supply chain. And these drug shortages remain high, despite decades of continued and increased awareness, effort and significant resource investment in these drug shortage programs at the highest level." At Mayo Clinic, the Pharmacy and Theruapuetics Committee has strategies and an organized approach to managing each drug shortage that's encountered."We engage our staff right down to the front-line team members when we're experiencing a shortage," says Dr. Gilmer. "When we place an order for a medication, and we do not receive sufficient quantities of what we're needing to take care of our patients, that's when we start escalating it, and really coordinating around how we understand and identify shortages so that we can best proactively manage them. So that's getting everybody on board for awareness, and any changes in our electronic health system that we need — or engaging our formulary colleagues to understand what alternatives or substitutes we can use." In addition to work done internally, Mayo Clinic also has taken a leadership role in combating drug shortages across the U.S., including joining the End Drug Shortages Alliance. The coalition is a collaboration of health system, supply chain and industry partners seeking to prevent drug shortages by solving pharmaceutical supply challenges and increasing transparency.Mayo was also a founding member of Civica Rx, a nonprofit generic drug company whose goal is to reduce shortages of essential medications that hospitals use. Civica Rx recently announced plans to manufacture and distribute affordable insulin. "We often talk about mitigating the impact of a drug shortage, but our goal is really to get further upstream and actually end them and stop them from happening,"says Dr. Eric Tichy, chair of the Division of Pharmacy Supply Solutions at Mayo Clinic. "So we do a lot of advocacy with the government and different regulatory agencies. And anytime someone says they want to help end or manage drug shortages, we're always interested in what that opportunity is."On the Mayo Clinic Q&A podcast, Drs. Gilmer and Tichy discuss Mayo Clinic's work to combat drug shortages. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy